• Stemtech posted a net loss of USD 1.25 million for the quarter ended March 31, 2026, narrowing 14.1% year over year.
• Net sales fell 46.67% to USD 462,957, hit by reduced inventory across key product lines that constrained order fulfillment.
• Operating loss improved to USD 1.09 million as operating expenses dropped to USD 1.45 million.
• Interest expense declined to USD 97,659; a USD 60,972 loss on extinguishment of debt was recorded on convertible note conversions.
• In April 2026, financing was secured to support production of about USD 2.5 million of inventory to improve product availability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stemtech Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-005028), on June 22, 2026, and is solely responsible for the information contained therein.